Novel Treatment Options in Patients with Maturity-Onset Diabetes of the Young

Abstract

Maturity-onset diabetes of the young (MODY) is the most common monogenetic form of diabetes with an autosomal dominant inheritance pattern. MODY is caused by mutations in genes important for the development and function of pancreatic beta cells, resulting in impaired insulin secretion capacity. To date, 14 different types have been described. While glucokinase (GCK)-MODY (formerly MODY-2) generally requires no drug therapy, other forms of MODY, such as hepatocyte nuclear factor-1-alpha (HNF1A)-MODY (formerly MODY-3) and HNF4A (formerly MODY-1), usually respond very well to sulfonylurea therapy. However, these MODY forms are characterised by a progressive course, meaning that insulin therapy is often required as the disease progresses. Both sulfonylurea therapy and insulin therapy are associated with an increased risk of hypoglycaemia and frequent weight gain. Newer blood glucose-lowering therapies, such as SGLT2 inhibitors (SGLT2i), DPP-4 inhibitors (DPP4i) and GLP-1 receptor agonists (GLP-1RA), have a much lower risk of hypoglycaemia and usually have a favourable effect on body weight. This review aims to provide an overview of the treatment of MODY patients with SGLT2i, DPP4i and GLP-1RA on the basis of previously published clinical studies, case series and case reports.

Keywords

MODY - SGLT2 inhibitor - gliflozin - DPP-4 inhibitor - gliptin - GLP-1 receptor agonist - GLP-1 analogue

Publication History

Received: 28 June 2024

Accepted: 08 October 2024

Accepted Manuscript online:
08 October 2024

Article published online:
22 November 2024

• References

• 1 GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021. Lancet 2023; 402: 203-234
• 2 Emmelheinz M, Knebel B, Müssig K. Diagnosis and Treatment of Maturity-Onset Diabetes of the Young (MODY). Diabetol Stoffwechs 2021; 16: 378-391
• 3 Gardner DS, Tai ES. Clinical features and treatment of maturity onset diabetes of the young (MODY). Diabetes Metab Syndr Obes 2012; 5: 101-108
• 4 Isomaa B, Henricsson M, Lehto M. et al. Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia 1998; 41: 467-473
• 5 Steele AM, Shields BM, Shepherd M. et al. Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene. Diabet Med 2010; 27: 157-161
• 6 Lyu B, Hwang YJ, Selvin E. et al. Glucose-lowering agents and the risk of hypoglycemia: A real-world study. J Gen Intern Med 2023; 38: 107-114
• 7 Hohendorff J, Szopa M, Skupien J. et al. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus. Endocrine 2017; 57: 272-279
• 8 Phan F, Bourron O, Laroche S. et al. Euglycaemic diabetic ketosis decompensation under dapagliflozin in a patient with MODY3. Diabetes Metab 2021; 47: 101248
• 9 Sriravindrarajah A, Fernandes A, Wu T. et al. The use of SGLT2 inhibitors in achieving glycaemic control in maturity-onset diabetes of the young type 3. Endocrinol Diabetes Metab Case Rep 2021; 2021: 21-0102
• 10 Brodosi L, Baracco B, Mantovani V. et al. NEUROD1 mutation in an Italian patient with maturity onset diabetes of the young 6: A case report. BMC Endocr Disord 2021; 21: 202
• 11 Ovsyannikova AK, Rymar OD, Shakhtshneider EV. et al. ABCC8-related maturity-onset diabetes of the young (MODY12): Clinical features and treatment perspective. Diabetes Ther 2016; 7: 591-600
• 12 Tonouchi R, Mine Y, Aoki M. et al. Efficacy and safety of alogliptin in a pediatric patient with maturity-onset diabetes of the young type 1. Clin Pediatr Endocrinol 2017; 26: 183-188
• 13 Koliaki C, Knebel B, Machicao F. et al. A rare cause of diabetes mellitus. Dtsch Med Wochenschr 2016; 141: 1025
• 14 Lumb AN, Gallen IW. Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1). Diabet Med 2009; 26: 189-190
• 15 Katra B, Klupa T, Skupien J. et al. Dipeptidyl peptidase-IV inhibitors are efficient adjunct therapy in HNF1A maturity-onset diabetes of the young patients – report of two cases. Diabetes Technol Ther 2010; 12: 313-316
• 16 Tan CSH, Ang SF, Lim SC. Response to multiple glucose-lowering agents in a sib-pair with a novel HNF1α (MODY3) variant. Eur J Hum Genet 2020; 28: 518-520
• 17 Christensen AS, Hædersdal S, Støy J. et al. Efficacy and safety of glimepiride with or without linagliptin treatment in patients with HNF1A diabetes (Maturity-Onset Diabetes of the Young Type 3): A randomized, double-blinded, placebo-controlled, crossover trial (GLIMLINA). Diabetes Care 2020; 43: 2025-2033
• 18 Mangrum C, Rush E, Shivaswamy V. Genetically targeted dipeptidyl peptidase-4 inhibitor use in a patient with a novel mutation of MODY type 4. Clin Med Insights Endocrinol Diabetes 2015; 8: 83-86
• 19 Yoshiji S, Horikawa Y, Kubota S. et al. First Japanese family with PDX1-MODY (MODY4): A novel PDX1 frameshift mutation, clinical characteristics, and implications. J Endocr Soc 2021; 6: bvab159
• 20 Zhou Y, Sun Y, Xu C. et al. ABCC8-related maturity-onset diabetes of the young: Clinical features and genetic analysis of one case. Pediatr Diabetes 2022; 23: 588-596
• 21 Broome DT, Tekin Z, Pantalone KM. et al. Novel use of GLP-1 receptor agonist therapy in HNF4A-MODY. Diabetes Care 2020; 43: e65
• 22 Ahluwalia R, Perkins K, Ewins D. et al. Exenatide-a potential role in treatment of HNF1-alpha MODY in obese patients?. Diabet Med 2009; 26: 834-835
• 23 Østoft SH, Bagger JI, Hansen T. et al. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: A double-blind, randomized, crossover trial. Diabetes Care 2014; 37: 1797-1805
• 24 Docena MK, Faiman C, Stanley CM. et al. Mody-3: Novel HNF1A mutation and the utility of glucagon-like peptide (GLP)-1 receptor agonist therapy. Endocr Pract 2014; 20: 107-111
• 25 Urakami T, Habu M, Okuno M. et al. Three years of liraglutide treatment offers continuously optimal glycemic control in a pediatric patient with maturity-onset diabetes of the young type 3. J Pediatr Endocrinol Metab 2015; 28: 327-331
• 26 Fantasia KL, Steenkamp DW. Optimal glycemic control in a patient with HNF1A MODY with GLP-1 RA monotherapy: Implications for future therapy. J Endocr Soc 2019; 3: 2286-2289
• 27 Terakawa A, Chujo D, Yasuda K. et al. Maturity-onset diabetes of the young type 5 treated with the glucagon-like peptide-1 receptor agonist: A case report. Medicine 2020; 99: e21939
• 28 Almutair A, Almulhem B. Semaglutide as a potential therapeutic alternative for HNF1B-MODY: A case study. Front Endocrinol 2024; 15: 1294264
• 29 Li J, Wang X, Mao H. et al. Precision therapy for three Chinese families with maturity-onset diabetes of the young (MODY12). Front Endocrinol 2022; 13: 858096
• 30 Nakhleh A, Goldenberg-Furmanov M, Goldstein R. et al. A beneficial role of GLP-1 receptor agonist therapy in ABCC8-MODY (MODY 12). J Diabetes Complications 2023; 37: 108566